Business Description
Paratek Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US6993743029
Description
Paratek Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's medical research is based on tetracycline chemistry and biology to create two antibacterials: omadacycline and sarecycline. NUZYRA (Omadacycline) is an antibacterial for skin infections and treatment of community-acquired bacterial pneumonia. SEYSARA (Sarecycline) is designed for use in the treatment of acne and rosacea. Paratek Pharmaceuticals is also involved in research to treat multiple sclerosis, spinal muscular atrophy, and systemic inflammatory diseases such as rheumatoid arthritis and inflammatory bowel diseases.
Financial Strength
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.16 | |||||
| Equity-to-Asset | -1.38 | |||||
| Debt-to-Equity | -1.29 | |||||
| Debt-to-EBITDA | -5.75 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | -9.69 | |||||
| Beneish M-Score | -3.21 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 79.3 | |||||
| 3-Year EBITDA Growth Rate | 36.7 | |||||
| 3-Year EPS without NRI Growth Rate | 32.2 | |||||
| 3-Year FCF Growth Rate | 32.2 | |||||
| 3-Year Book Growth Rate | -47.1 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 6-1 Month Momentum % | 13.33 | |||||
| 12-1 Month Momentum % | -11.95 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.52 | |||||
| Quick Ratio | 0.46 | |||||
| Cash Ratio | 0.21 | |||||
| Days Inventory | 220.62 | |||||
| Days Sales Outstanding | 92.07 | |||||
| Days Payable | 70 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -12.5 | |||||
| Shareholder Yield % | -13.98 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 84.91 | |||||
| Operating Margin % | -26.89 | |||||
| Net Margin % | -37.77 | |||||
| FCF Margin % | -13.86 | |||||
| ROA % | -39.95 | |||||
| ROIC % | -41.37 | |||||
| ROC (Joel Greenblatt) % | -125.64 | |||||
| ROCE % | -48.67 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 111.11 | |||||
| PS Ratio | 0.71 | |||||
| EV-to-EBIT | -7.71 | |||||
| EV-to-EBITDA | -7.77 | |||||
| EV-to-Revenue | 2.04 | |||||
| EV-to-Forward-Revenue | 1.48 | |||||
| EV-to-FCF | -14.18 | |||||
| Earnings Yield (Greenblatt) % | -12.97 | |||||
| FCF Yield % | -19.03 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:PRTK
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Paratek Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 167.742 | ||
| EPS (TTM) ($) | -1.1 | ||
| Beta | 0 | ||
| Volatility % | 99.77 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR ($) | 0.011986 | ||
| 20-Day SMA ($) | 0 | ||
| 12-1 Month Momentum % | -11.95 | ||
| 52-Week Range ($) | 1.29 - 3.65 | ||
| Shares Outstanding (Mil) | 57.32 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Paratek Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Paratek Pharmaceuticals Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Paratek Pharmaceuticals Inc Frequently Asked Questions
What is Paratek Pharmaceuticals Inc(PRTK)'s stock price today?
The current price of PRTK is $2.23. The 52 week high of PRTK is $3.65 and 52 week low is $1.29.
When is next earnings date of Paratek Pharmaceuticals Inc(PRTK)?
The next earnings date of Paratek Pharmaceuticals Inc(PRTK) is 2025-03-15 Est..
Does Paratek Pharmaceuticals Inc(PRTK) pay dividends? If so, how much?
Paratek Pharmaceuticals Inc(PRTK) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers